Intralytix, Inc. enters into a collaboration agreement with the G. N. Gabrichevsky Research Institute for Epidemiology and Microbiology (GRIEM) (Moscow, Russia).

Baltimore, Maryland, U.S.A. November 27, 2017. Intralytix, Inc. announced today that it entered into a collaboration agreement with the G. N. Gabrichevsky Research Institute for Epidemiology and Microbiology (GRIEM) (Moscow, Russia) for developing bacteriophage preparations against selected bacterial pathogens.

"Our colleagues at the Gabrichevsky Institute have considerable experience in working with bacteriophages, and we are pleased to have entered into this collaboration with Dr. Andrey Aleshkin's group at the Institute" stated Alexander Sulakvelidze, Intralytix's Executive Vice-President and Chief Scientific Officer of the Company. He added "We are looking forward to a successful collaboration with the GRIEM and to expanding our R&D activities in Russia."

"Intralytix is the world leader in developing FDA-approved bacteriophage-based preparations for various applications" commented Dr. Andrey Aleshkin, Head of the Laboratory at the GRIEM and the Principal Investigator on the Intralytix contract. He added "We look forward to a fruitful partnership with Intralytix and to sharing our experiences in the range of topics from early phage isolation and development to the regulatory strategies required for approving phage products both in Russia and in the United States."

For more information, contact:

Dr. Alexander Sulakvelidze (410-625-2533 asulakvelidze@intralytix.com) or Dr. Andrey Aleshkin (+7 495-452-18-16 andreialeshkin@googlemail.com).